Molnupiravir: From Hope to Epic Fail?
Molnupiravir: From Hope to Epic Fail?
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far. However, it has recently been associated with very poor clinical efficacy, the risk of creating novel SARS-CoV-2 variants of concern, and long-term risk for mutagenicit...
Alternative Titles
Full title
Molnupiravir: From Hope to Epic Fail?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_56e630f1cd02425ebc4c065d70cffb4c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_56e630f1cd02425ebc4c065d70cffb4c
Other Identifiers
ISSN
1999-4915
E-ISSN
1999-4915
DOI
10.3390/v14112560
